Ayala Pharmaceuticals Inc (OTCMKTS:ADXS) Stock In Focus After Recent News
Clinical stage oncology company Ayala Pharmaceuticals Inc (OTCMKTS:ADXS) is one of the companies that could be worth tracking this week in light of the announcement from the company this morning. The company announced additional results from the Phase 2 segment of the RINGSIDE study related to the evaluation of AL102 in patients suffering from desmoid tumours.
Trading Data
On Monday, ADXS stock decreased 3.12% to $1.2400 with more than 12.93K shares, compared to its average volume of 6.84K shares. The stock moved within a range of $1.1200 – 1.3000 after opening trade at $1.2450.
Updated RINGSIDE Phase 2 Results Featured in Poster Discussion Session at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
The results from the study had then been presented as part of a poster discussion session held at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting this past Saturday. The product in question is a potent, oral gamma-secretese inhibitor that is supposed to be consumed once daily.
Dr. Mrinal M Gounder, who is a medical oncologist at the Memorial Sloan Kettering Cancer Center in New York spoke about the merits of gamma-secretese inhibitors. He noted that the inhibitors had actually emerged as a promising new class of drugs for managing desmoid tumours since it had the potential of tolerability, tumour regression and symptomatic improvement. He went on to add that the latest data from the Phase 2 study revealed that AL102 had been active in desmoid tumours and responses to the treatment had also been noticed in all the test groups.
